As of 2024-12-11, the Relative Valuation of Akero Therapeutics Inc (AKRO) is (94.48) USD. This relative valuation is based on P/E multiples. With the latest stock price at 30.64 USD, the upside of Akero Therapeutics Inc based on Relative Valuation is -408.4%.
The range of the Relative Valuation is (96.38) - (106.99) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 28.4x - 45.2x | 35.0x |
| Forward P/E multiples | 19.9x - 31.5x | 20.6x |
| Fair Price | (96.38) - (106.99) | (94.48) |
| Upside | -414.6% - -449.2% | -408.4% |
| Date | P/E |
| 2024-11-29 | -9.45 |
| 2024-11-27 | -9.47 |
| 2024-11-26 | -9.17 |
| 2024-11-25 | -9.35 |
| 2024-11-22 | -9.63 |
| 2024-11-21 | -9.18 |
| 2024-11-20 | -9.01 |
| 2024-11-19 | -9.13 |
| 2024-11-18 | -8.70 |
| 2024-11-15 | -8.27 |
| 2024-11-14 | -8.76 |
| 2024-11-13 | -9.11 |
| 2024-11-12 | -9.53 |
| 2024-11-11 | -9.72 |
| 2024-11-08 | -10.14 |
| 2024-11-07 | -10.26 |
| 2024-11-06 | -10.38 |
| 2024-11-05 | -9.63 |
| 2024-11-04 | -9.43 |
| 2024-11-01 | -9.51 |
| 2024-10-31 | -9.07 |
| 2024-10-30 | -9.03 |
| 2024-10-29 | -9.34 |
| 2024-10-28 | -8.74 |
| 2024-10-25 | -8.63 |
| 2024-10-24 | -8.46 |
| 2024-10-23 | -8.44 |
| 2024-10-22 | -8.71 |
| 2024-10-21 | -9.09 |
| 2024-10-18 | -9.19 |
| 2024-10-17 | -9.07 |
| 2024-10-16 | -9.14 |
| 2024-10-15 | -8.81 |
| 2024-10-14 | -8.83 |
| 2024-10-11 | -8.72 |
| 2024-10-10 | -8.56 |
| 2024-10-09 | -8.39 |
| 2024-10-08 | -8.28 |
| 2024-10-07 | -7.87 |
| 2024-10-04 | -8.31 |
| 2024-10-03 | -8.14 |
| 2024-10-02 | -8.59 |
| 2024-10-01 | -8.48 |
| 2024-09-30 | -8.44 |
| 2024-09-27 | -8.31 |
| 2024-09-26 | -8.63 |
| 2024-09-25 | -8.24 |
| 2024-09-24 | -8.25 |
| 2024-09-23 | -8.35 |
| 2024-09-20 | -8.26 |